Vol. 14 No. 3 (2022)

Artigos

• Economic analysis of private health and insurance plans: is there rationality in the regulation that induces preventive strategy?

  Eduardo Henrique Franklin

  204-209

  • PDF (Português (Brasil))

• Hospital costs reduction after implementation of informatized tools in the logistics of a hospital pharmacy service

  Cássio Rodrigues, Vaneska Paiva

  210-216

  • PDF (Português (Brasil))

• The impact of the COVID-19 pandemic on cancer screening tests in Brazil: a comparative study of breast, prostate, and cervical cancers

  Isabela Oliveira, Manuela Mandel, Luciana Holtz, André Santos, Marcus Vinícius Barbosa, Marcelo Carloni, Otávio Augusto Clark

  217-223

  • PDF (Português (Brasil))

• Time-Driven Activity Based Costing (TDABC) of the CEDMAC model of assisted therapy for dispensing immunobiological rheumatologic medications at SUSTime-Driven Activity Based Costing (TDABC) of the CEDMAC model of assisted therapy for dispensing immuno

  Michelle Lopes, Julio Cesar Moraes, Eloisa Bonfá, Hugo Gegembauer

  224-231

  • PDF (Português (Brasil))

• Direct costs associated with lupus nephritis management in the Private Healthcare System in Brazil: an expert panel perspective

  Danielle O. Silva, Nathalie David, Bruce Y. Kano, Diego Kashiura, Odirlei A. Monticielo, André Hayata, Mariana R. Gazzotti, Graziela Bernardino

  232-246

  • PDF

• Cost comparison of dupilumab and omalizumab for the treatment of severe allergic asthma patients from the Brazilian private healthcare system perspective

  Frederico Magro, Aline Barbosa, Alexandre Taminato, Celina Migliavaca, Priscila Federico, Renata Tebyriçá, Jose Eduardo D. Cançado, Pedro Giavina-Bianchi, Maicon Falavigna

  247-252

  • PDF

• Pharmaceutical interventions in Emergency Care Unit: a pharmacotherapeutic and pharmacoeconomic analysis

  Mateus Augusto Lima, Michele Rosa, Daisid Meyrelles

  253-258

  • PDF (Português (Brasil))

• A Multicriteria Decision Analysis (MCDA) framework to identify and prioritize criteria for guiding decision making for postmenopausal osteoporosis treatment in the Brazilian Public Healthcare System

  Luciana L. Mensor, Mariana P. Rosim, Thiago H. M. Marchesan, Deborah Rigo, Frederico Sallum, Laura Amaral

  259-266

  • PDF (Português (Brasil))

• Comment on: Immunotherapy-based first-line treatment of intermediate- and poor-risk advanced renal cell carcinoma: number needed to treat and cost of preventing an event from the perspective of the Brazilian private healthcare system

  Letícia Paula Leonart, Bruno Riveros, Felipe Berlinski, Maria Aparecida Rego

  267-268

  • PDF

• The use of real-world-data in economic analysis for rare disease: the Costs of Hemophilia in Brazil

  Ana Paula Etges, Nayê Schneider, Erica Roos, Veronica Mata, Carisi Anne Polanczyk

  269-271

  • PDF (Português (Brasil))

• Analysis of epidemiological and economic data of hemophilia A patients in Brazil

  Túlio Sarmento, Renato Picoli, Marília Renni, Yukie Sato-Kuwabara, Verônica Elizabeth Mata

  272-281

  • PDF